A practical review on carfilzomib in multiple myeloma
Author:
Affiliation:
1. Division of Hematology; Mayo Clinic; Rochester; MN USA
2. Institute of Hematology; Davidoff Cancer Center; Beilinson Hospital; Rabin Medical Center; Petah-Tikva Israel
3. Sackler School of Medicine; Tel-Aviv University; Tel-Aviv; Israel
Publisher
Wiley
Subject
Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12749/fullpdf
Reference53 articles.
1. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia;Wartman;Leuk Lymphoma,2015
2. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia;Treon;Blood,2014
3. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors;Papadopoulos;Cancer Chemother Pharmacol,2013
4. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide;Wang;Leuk Lymphoma,2014
5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study;Dimopoulos;Lancet Oncol,2016
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Fabrication of Poly Lactic-co-Glycolic Acid Microneedles for Sustained Delivery of Lipophilic Peptide-Carfilzomib;Molecular Pharmaceutics;2024-09-10
2. Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma;Bioorganic & Medicinal Chemistry;2024-09
3. Carfilzomib-induced pulmonary hypertension in a patient with multiple myeloma;Journal of Cardiology Cases;2024-08
4. PSMD1 as a prognostic marker and potential target in oropharyngeal cancer;BMC Cancer;2023-12-16
5. PSMD1 as a Prognostic Marker and Potential Target in Head and Neck Cancer;2023-09-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3